Welcome to our dedicated page for AVROBIO news (Ticker: AVRO), a resource for investors and traders seeking the latest updates and insights on AVROBIO stock.
AVROBIO, Inc. (symbol: AVRO) is a pioneering clinical-stage gene therapy company dedicated to transforming the lives of patients with cancer and rare genetic diseases. The company focuses on developing potentially curative ex vivo lentiviral gene therapies, offering hope for long-term, potentially lifelong benefits from a single-dose treatment regimen.
AVROBIO's innovative pipeline includes several promising product candidates:
- AVR-RD-04: Designed for the treatment of cystinosis, a rare metabolic disorder that can lead to kidney and eye complications.
- AVR-RD-02: Targeting Gaucher disease type 1, which affects the spleen, liver, and bone marrow, this therapy aims to significantly improve patients' quality of life.
- AVR-RD-05: Developed to combat Hunter syndrome (MPS II), a disorder impacting cognitive development and physical health.
- AVR-RD-03: Intended for the treatment of Pompe disease, a condition that leads to progressive muscle weakness and respiratory failure.
AVROBIO is committed to advancing its clinical programs and leveraging strategic partnerships to enhance the development and commercialization of its therapies. The company continually updates the market with the latest progress and achievements through press releases and collaborations with other industry leaders.
The latest news from AVROBIO includes significant updates on clinical trials, technological advancements, and strategic partnerships. For instance, new collaborations with Tectonic Therapeutic, Inc. underscore AVROBIO's commitment to innovation and expanding its therapeutic reach. Financially, AVROBIO remains focused on maintaining a solid financial foundation to support its ambitious research and development activities.
With a mission to deliver transformative therapies to patients with unmet medical needs, AVROBIO is at the forefront of the gene therapy revolution, continually pushing the boundaries of what is possible in the treatment of rare diseases.
AVROBIO, Inc. reported 2022 financial results, showing a net loss of $105.9 million for the year, improving from $119.1 million in 2021. The company plans to initiate a global Phase 2/3 trial for Gaucher disease type 3 in late 2023 after receiving favorable regulatory feedback. Additionally, dosing in a Phase 1/2 trial for cystinosis has completed, with updates expected at the ASGCT annual meeting in May 2023. AVROBIO ended 2022 with $92.6 million in cash, sufficient to fund operations into Q1 2024. Research and development expenses decreased to $72.2 million for the year, compared to $83.1 million in 2021.
AVROBIO, a clinical-stage gene therapy company, will have its senior management participate in the 'Orphan Neuro Corporate Panel' at Cowen’s 43rd Annual Health Care Conference on March 7, 2023, at 10:30 AM ET in Boston. This event highlights AVROBIO's commitment to addressing genetic diseases through innovative gene therapies. The panel will be webcast live and archived for 90 days on avrobio.com. AVROBIO is focused on developing treatments for conditions such as Gaucher disease and cystinosis using its proprietary plato® platform, aimed at durable therapeutic benefits.
AVROBIO (Nasdaq: AVRO) announced the presentation of updated data at the 19th Annual WORLD Symposium in Orlando, Florida, from February 22-26, 2023. The reports include promising results showing complete biochemical correction in the first pediatric Gaucher disease type 3 patient treated with hematopoietic stem cell gene therapy. Furthermore, data from a fully enrolled Phase 1/2 clinical trial in cystinosis will also be shared. Key presentations on gene therapy for mucopolysaccharidosis type II and ongoing clinical trials for Gaucher and cystinosis will be highlighted, emphasizing AVROBIO's commitment to advancing gene therapy solutions.
AVROBIO, Inc. (Nasdaq: AVRO) announced the granting of 7,500 restricted stock units (RSUs) to a new employee as an inducement award under its 2019 Inducement Plan. The RSUs were granted on
AVROBIO has released new interim data on its investigational gene therapy AVR-RD-02 for Gaucher disease, showcasing positive outcomes from both pediatric GD3 and adult GD1 patients. A pediatric patient demonstrated complete biochemical correction and significant health improvements 15 months post-treatment. Additionally, the first four adult patients in a GD1 trial showed important reductions in liver and spleen volume up to two years post-therapy. Following favorable discussions with regulatory bodies, a global registrational Phase 2/3 clinical trial for GD3 is set for late 2023.
AVROBIO, Inc. (NASDAQ: AVRO) announced a virtual update on its Gaucher Disease Program for analysts and investors scheduled for December 7, 2022, at 8 am ET. The update will cover advancements in its clinical program focused on Gaucher disease, including new pharmacodynamic and efficacy data extending to two years post-gene therapy. The company will also discuss a prospective Phase 2/3 clinical trial and its overall development strategy. Guests will include experts in lysosomal disorders and pediatric stem cell transplants.
AVROBIO, a gene therapy company, reported its third quarter financial results for 2022, highlighting a decrease in net loss to $23 million from $32.6 million in 2021. Research and development expenses fell to $15.9 million, driven by reduced program development costs. The company also received rare pediatric disease designations for its investigational therapies for Gaucher disease and cystinosis. A comprehensive update on the Gaucher disease program is scheduled for December 7, 2022. As of September 30, 2022, AVROBIO had $116 million in cash, expected to support operations into Q1 2024.
AVROBIO (NASDAQ: AVRO) announced participation in a virtual panel on 'Genomic Medicines – Evolving Regulatory Environment and Path to Approval' at the Sixth Annual Barclays Gene Editing/Therapy Summit.
The event is scheduled for Monday, Nov. 14, 2022, at 12:30 PM ET. AVROBIO focuses on gene therapy for genetic diseases, including cystinosis and Gaucher disease, utilizing its proprietary plato® platform to enhance clinical development.
AVROBIO, a clinical-stage gene therapy company, announced the granting of 13,000 restricted stock units (RSUs) to two new employees under its 2019 Inducement Plan. These RSUs were awarded on November 1, 2022, to encourage the new hires' acceptance of employment. The RSUs will vest over four years, with the initial 25% vesting after one year and the remainder vesting annually thereafter. This initiative aligns with Nasdaq Listing Rule 5635(c)(4), reinforcing the company's commitment to talent acquisition.
AVROBIO, Inc. announced that the FDA granted Rare Pediatric Disease Designation to its investigational gene therapy AVR-RD-02 for treating Gaucher disease. This designation aims to facilitate drug development for rare pediatric diseases and offers potential benefits, including a priority review voucher for future applications. AVR-RD-02 targets Gaucher disease type 1 and type 3, affecting approximately 30,000 patients globally. Interim clinical data updates are expected in Q4 2022.
FAQ
What is the current stock price of AVROBIO (AVRO)?
What is the market cap of AVROBIO (AVRO)?
What does AVROBIO, Inc. specialize in?
What are the key products in AVROBIO's pipeline?
How does AVROBIO's gene therapy work?
What recent achievements has AVROBIO announced?
What is the financial condition of AVROBIO?
Who are AVROBIO's partners in their gene therapy development?
What is the significance of AVROBIO's work on rare diseases?
What is ex vivo lentiviral gene therapy?
How does AVROBIO intend to deliver their therapies to patients?
Where can I find the latest news about AVROBIO?
